Lucid MS
Alternative Names: Lucid-21-302; Lucid-MSLatest Information Update: 16 Mar 2025
At a glance
- Originator University Health Network
- Developer FSD Pharma; Lucid Psycheceuticals
- Class Neuroprotectants; Small molecules
- Mechanism of Action Protein-arginine deiminase inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Multiple sclerosis
Most Recent Events
- 16 Mar 2025 Huge Biopharma Australia completes a phase I trial in Multiple sclerosis (In volunteers) in Australia (PO) (NCT06595706)
- 28 Sep 2024 Phase-I clinical trials in Multiple sclerosis (In volunteers) in Australia (PO) (NCT06595706)
- 29 Feb 2024 Pharmacokinetics and adverse events data from a phase I trial in Multiple sclerosis presented at Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2024 (CTRIMS-2024)